-
公开(公告)号：US20190085291A1
公开(公告)日：2019-03-21
申请号：US16099551
申请日：2017-05-31
发明人： Guy SAUVAGEAU , Iman FARES , Jalila CHAGRAOUI
IPC分类号： C12N5/0789 , A61K35/28
摘要： It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.
-
2.发明授权公开(公告)号：US12092903B2
公开(公告)日：2024-09-17
申请号：US17283458
申请日：2019-10-09
IPC分类号： G02C7/02
摘要： A system and method for determining an adapted ophthalmic device for a wearer, the method including acquiring a set of parameters values relating to the wearer, determining at least a task to be performed by the wearer involving visual exploration, using a computing system, determining a value of a criterion assessing an efficiency of the wearer's visual exploration strategy for the task, and determining an optical design of an ophthalmic device to be worn by a wearer according to the determined value of the criterion.
-
公开(公告)号：US11493782B2
公开(公告)日：2022-11-08
申请号：US16763648
申请日：2018-11-23
摘要： There is described a medical device for management of the axial length growth of an eye of a subject. The device comprises a central region having a first power, a transition region surrounding the central region, and a peripheral region surrounding the transition region and having a second power. The transition region has a width at most equal to 1.5 mm. The second power is chosen based on the first power to achieve a target net power, the target net power being the addition of the first power and the second power. The surface area of the central and peripheral regions is chosen as a function of the surface area of the pupil of the eye. Furthermore, the curve of power within the transition region is steep between the first power and the second power so that the transition region generates no optically usable power.
-
4.发明申请公开(公告)号：US20220284303A1
公开(公告)日：2022-09-08
申请号：US17632718
申请日：2020-08-03
摘要： A system simulating a decisional process in a mammal brain about characteristics of motions related to body gestures of a visually observed body through a simulated visual path is provided. The system includes an interface toward simulated neuronal structures, the interface at least converting luminous information of the observed body to an optic flow data stream conveying information related to the visually observed body and that can be processed in the simulated neuronal structures, the system being a feed-forward system and comprising hierarchically from the visual observation to the decision: the simulated visual path and its interface, a simulated local motion direction detection neuronal structure for the detection of motion directions with receptive fields, a simulated opponent motions detection neuronal structure, a simulated complex patterns detection neuronal structure, and a simulated motion pattern detection neuronal structure.
-
公开(公告)号：US20220243070A1
公开(公告)日：2022-08-04
申请号：US17610217
申请日：2020-05-13
申请人： UNIVERSITE LAVAL , UNIVERSITE TOULOUSE III- PAUL SABATIER , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE DE MONTREAL
发明人： Gaétan LAROCHE , Ivan RODRIGUEZ DURAN , Luc STAFFORD , Julien VALLADE , Antoine DUROCHER-JEAN , Jacopo PROFILI , Nicolas GHERARDI , Raphaël COZZOLINO
IPC分类号： C09D5/00 , C09D1/00 , C08J7/06 , C08J7/054 , C03C17/00 , C03C17/245 , C23C16/40 , C23C16/503 , G02B1/18 , G02B1/12
摘要： The present disclosure relates to anti-fog coatings, coated substrate comprising an anti-fog coating and a process for preparing such coatings. Said process comprising exposing a surface to be coated in a plasma, said plasma produced by exposing a carrier gas comprising an oxidant (e.g. N2/O2, N2/N2O, or air) and a alkylcyclosiloxane (e.g. tetramethylcyclotetrasiloxane) under dielectric barrier discharge (DBD) in Townsend's mode at atmospheric pressure.
-
公开(公告)号：US11282501B2
公开(公告)日：2022-03-22
申请号：US16656700
申请日：2019-10-18
发明人： Sanghyun Yoo , Yoshua Bengio , Inchul Song
摘要： A speech recognition method and apparatus, including implementation and/or training, are disclosed. The speech recognition method includes obtaining a speech signal, and performing a recognition of the speech signal, including generating a dialect parameter, for the speech signal, from input dialect data using a parameter generation model, applying the dialect parameter to a trained speech recognition model to generate a dialect speech recognition model, and generating a speech recognition result from the speech signal by implementing, with respect to the speech signal, the dialect speech recognition model. The speech recognition method and apparatus may perform speech recognition and/or training of the speech recognition model and the parameter generation model.
-
公开(公告)号：US10377715B2
公开(公告)日：2019-08-13
申请号：US15833530
申请日：2017-12-06
申请人： HARO PHARMACEUTICAL INC. , THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY , UNIVERSITE DE MONTREAL
发明人： David Bettoun , Eduardo Martinez , James Gleason , Sylvie Mader , Shuo Xing
IPC分类号： C07D215/54 , C07D409/04 , C07C259/10 , C07D209/08 , C07D209/42 , C07D215/48
摘要： The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
-
公开(公告)号：US10342817B2
公开(公告)日：2019-07-09
申请号：US15407122
申请日：2017-01-16
IPC分类号： A61K45/06 , A61K31/4402 , A61K31/7056 , A61K31/7068
摘要： The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises ribavirin, GDC-0449 and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides a combination therapy for treating patients having leukemia.
-
公开(公告)号：US10329307B2
公开(公告)日：2019-06-25
申请号：US15767795
申请日：2016-09-19
发明人： Alain Martel , Francois Tremblay
IPC分类号： C07D513/04 , C07D487/04 , C07D498/04 , A61P7/02 , A61K31/433 , A61K31/454 , A61K31/4545 , A61K31/496
摘要： The present invention provides compounds of Formula I: wherein Y, AA, W, R3′ R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09862730B2
公开(公告)日：2018-01-09
申请号：US14396807
申请日：2013-04-24
发明人： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC分类号： C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377
CPC分类号： C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
摘要： The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
-
-
-
-
-
-
-
-
-
搜索结果
232 条记录 (耗时 0.044 秒)
